Patents Assigned to Deutsches Krebsforschungszentrum
  • Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
    Patent number: 9850308
    Abstract: The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: December 26, 2017
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS, UNIVERSITAETSKLINIKUM HEIDELBERG
    Inventors: Ana Martin-Villalba, Susanne Kleber, Benedikt Wiestler, Peter G. Krammer, Christel Herold-Mende, Ignacio Sancho-Martinez
  • PREDICTION OF RECURRENCE FOR BLADDER CANCER BY A PROTEIN SIGNATURE IN TISSUE SAMPLES
    Publication number: 20170336414
    Abstract: The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown in Table, and comparing the amount of said at least one biomarker with a reference amount for said at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted. The present invention also contemplates a method for identifying a subject being in need of a further bladder cancer therapy. Encompassed are, furthermore, diagnostic devices and kits for carrying out said methods.
    Type: Application
    Filed: May 8, 2017
    Publication date: November 23, 2017
    Applicants: Deutsches Krebsforschungszentrum, Institut Curie
    Inventors: Christoph SCHRODER, Harish SRINIVASAN, Jõrg HOHEISEL, François RADVANYI
  • 4Pi STED fluorescence light microscope with high three-dimensional spatial resolution
    Patent number: 9804375
    Abstract: An apparatus forming an area of minimum light intensity enclosed by high light intensity includes two objectives focusing light of opposite directions into a common focal area. Light intensities of a first pair of light beams extinguish each other in a first partial area of the focal area. Beam paths of the first pair of beams pass through the objectives in a first pair of partial areas of the pupils of the objectives. Light intensities of a second pair of light beams extinguish each other in a second partial area of the focal area. Beam paths of the second pair of light beams pass through the objectives in a second pair of partial areas which are offset with regard to the first pair of partial areas of the pupils; and the light of the second pair does not interfere with the light of the first pair of light beams.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: October 31, 2017
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventor: Johann Engelhardt
  • Diagnostic transcript and splice patterns of HPV16 in different cervical lesions
    Patent number: 9803253
    Abstract: A method is described for differentiating in a subject with HPV16 between (i) a severe form of HPV16 infection and (ii) a mild form of HPV16 infection based on determining the amount of a first gene product and a second gene product in a sample of a subject and calculating a ratio of the amount of the first gene product and the amount of the second gene product. A composition is also described, including an oligonucleotide mixture, and also a kit and a device adapted to carry out the described method.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: October 31, 2017
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Markus Schmitt, Lutz Gissmann, Michael Pawlita
  • Adenovirus derived helper virus for enhancing recombinant parvovirus production
    Patent number: 9803219
    Abstract: Described is an adenovirus derived helper virus which may comprise the adenoviral DNA sequences for E2a, S4 (orf6), the VA1 RNA gene, and the parvovirus VP capsid gene unit. Also described is a method of efficiently preparing a recombinant parvovirus (particle) which is based on the use of various adenoviral derived helper viruses/vectors.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: October 31, 2017
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Nazim El-Andaloussi, Antonio Marchini, Jean Rommelaere, Barbara Leuchs, Max Endele
  • USE OF PARVOVIRUS FOR ELIMINATING CANCER STEM CELLS (CSCs)
    Publication number: 20170266244
    Abstract: Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.
    Type: Application
    Filed: June 8, 2017
    Publication date: September 21, 2017
    Applicants: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universitaet Heidelberg
    Inventors: Jean Rommelaere, Jeannine Lacroix, Joerg Schlehofer, Olaf Witt, Elisabeth Hedwig Deubzer, Sonja Kern, Christel Herold-Mende, Karsten Geletneky, Barbara Leuchs
  • METHOD FOR THE DETECTION OF ANTIGEN PRESENTATION
    Publication number: 20170254803
    Abstract: The present invention pertains to a method for detecting antigen presentation via antigen presenting molecules such as major histocompatibility complex (MHC) class I or II. The invention deploys a first binding agent specific for the antigen epitope and a second binding agent specific for the antigen presenting molecule. The binding agents of the invention are coupled to proximity probes which upon antigen presentation elicit a detectable signal. The method of the invention allows detecting antigen presentation via MHC in-vitro and in a tissue sample in-situ. Thus the method of the present invention finds application as a new diagnostic tool, for example in the diagnosis of various diseases such as infectious diseases, immunological disorders, in particular autoimmune diseases, and proliferative disorders such as cancer.
    Type: Application
    Filed: October 22, 2015
    Publication date: September 7, 2017
    Applicant: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
    Inventors: Michael PLATTEN, Wolfgang WICK, Lukas BUNSE, Theresa BUNSE, Felix SAHM
  • Method and devices for applying substances to a support, especially monomers for the combinatorial synthesis of molecule libraries
    Patent number: 9752985
    Abstract: For the combinatorial synthesis of molecule libraries, substances are embedded in a matrix consisting of a first solvent thereby forming transport units in a solid state of aggregation at a temperature of less than 90° C. and wherein after application to a support, the physical environment of the transport units is modified by the application of a physical process such as a laser printer whereby the substances in the transport units are linked to the support.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: September 5, 2017
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS, EUROPÄISCHES LABORATORIUM FÜR MOLEKULARBIOLOGIE
    Inventors: Annemarie Poustka, Frank Breitling, Karl-Heinz Gross, Stefan Dübel, Rainer Saffrich
  • NOROVIRUS ANTIBODIES
    Publication number: 20170247434
    Abstract: The present invention relates to a binding polypeptide specifically binding to the amino acid sequence W-V-N-X1-F-Y-X2 (SEQ ID NO: 1), wherein X1 represents any amino acid, preferably Q or P, and wherein X2 represents any amino acid, preferably, T or S in a norovirus polypeptide. The present invention further relates to polynucleotide encoding a binding polypeptide of the present invention an to a host cell comprising the same or the polynucleotide of the invention. The present invention further relates to a method of detecting the presence of a norovirus capsid polypeptide in a sample and to kits, devices, and uses making use of the binding peptide of the invention.
    Type: Application
    Filed: October 14, 2015
    Publication date: August 31, 2017
    Applicants: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universität Heidelberg
    Inventors: Grant HANSMAN, Anna KOROMYSLOVA
  • Use of parvovirus for eliminating cancer stem cells (CSCs)
    Patent number: 9700588
    Abstract: Described is the use of a parvovirus, preferably H-1PV, for the therapeutical elimination of cancer stem cells (CSCs), preferably neuroblastoma stem cells and glioblastoma stem cells.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: July 11, 2017
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
    Inventors: Jean Rommelaere, Jeannine Lacroix, Joerg Schlehofer, Olaf Witt, Elisabeth Hedwig Deubzer, Sonja Kern, Christel Herold-Mende, Karsten Geletneky, Barbara Leuchs
  • Circulating miRNAs as early detection marker and prognostic marker
    Patent number: 9683264
    Abstract: Provided is a novel method for the early detection and/or discrimination of cancer and anti-cancer agents for the prevention or early treatment of cancer. In particular, the method relates to the determination of levels of circulating miRNAs in breast cancer patients, both primary and metastatic. Furthermore, kits, devices, pharmaceutical compositions as well as methods related thereto are described.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: June 20, 2017
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAT
    Inventors: Barbara Burwinkel, Dharanija Madhavan
  • MEANS AND METHODS FOR DIAGNOSING PANCREATIC CANCER
    Publication number: 20170168062
    Abstract: The present invention pertains to the field of cancer diagnosis. Specifically, it relates to a method for diagnosing pancreas cancer in a subject comprising the steps of determining in a sample of a subject suspected to suffer from pancreas cancer the amount of at least one biomarker selected from the biomarkers shown in Table 1 and comparing the said amount of the at least one biomarker with a reference, whereby pancreas cancer is to be diagnosed. The present invention also contemplates a method for identifying whether a subject is in need of a pancreas cancer therapy comprising the steps of the aforementioned methods and the further step of identifying a subject in need of a pancreas cancer therapy if said subject is to be diagnosed to suffer from pancreas cancer. Contemplated are, furthermore, diagnostic devices and kits for carrying out said methods.
    Type: Application
    Filed: December 21, 2016
    Publication date: June 15, 2017
    Applicants: Deutsches Krebsforschungszentrum, Queen Mary University of London
    Inventors: Christoph SCHRÖDER, Jörg HOHEISEL, Tatjana CRNOGORAC-JURCEVIC
  • Rearranged TT virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
    Patent number: 9676828
    Abstract: The present invention relates to rearranged molecules of (a) a specific TT virus sequence and (b) a nucleotide sequence encoding a polypeptide showing homology to mammalian proteins associated with cancer and autoimmune diseases that are capable of replicating autonomously for use in diagnosis, prevention and treatment of diseases like cancer and autoimmunity.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: June 13, 2017
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Ethel-Michele De Villiers, Harald Zur Hausen
  • B7-H6 therapeutically active monoclonal antibody against B7-H6 polypeptide
    Patent number: 9676855
    Abstract: The present invention is concerned with diagnostic methods and means. Specifically, it relates to an antibody which specifically binds to a portion of the extracellular domain of the B7-H6 polypeptide. Moreover, said antibody is provided for use in the treatment or diagnosis of cancer or inflammatory disease. Furthermore, provided are a method for diagnosing cancer in a sample of a subject suspected to suffer from cancer or an inflammatory disease. Further, the present invention concerns a device and a kit for diagnosing cancer or an inflammatory.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: June 13, 2017
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Adelheid Cerwenka, Gerhard Moldenhauer
  • Prediction of recurrence for bladder cancer by a protein signature in tissue samples
    Patent number: 9678075
    Abstract: The present invention pertains to the field of cancer prediction. Specifically, it relates to a method for predicting the risk of recurrence of bladder cancer in a subject after treatment of bladder cancer comprising the steps of determining the amount of at least one biomarker selected from the biomarkers shown in Table, and comparing the amount of said at least one biomarker with a reference amount for said at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted. The present invention also contemplates a method for identifying a subject being in need of a further bladder cancer therapy. Encompassed are, furthermore, diagnostic devices and kits for carrying out said methods.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: June 13, 2017
    Assignees: Deutsches Krebsforschungszentrum, Institut Curie
    Inventors: Christoph Schröder, Harish Srinivasan, Jörg Hoheisel, François Radvanyi
  • RECEPTORS OF RSPO2 AND RSPO3
    Publication number: 20170153246
    Abstract: The present invention relates to the finding that Syndecans (Sdc) are receptors of Rspondin-2 (Rspo2) and Rspondin-3 (Rspo3). Thus, the present invention relates to the identification of Rspo2, Rspo3 and/or Sdc activity modulators by determining if a test compound has the ability to modulate the binding of an Rspo2 and/or Rspo3 polypeptide to an Sdc polypeptide. Further, the invention refers to novel uses for antagonists of Rspo2 and/or Rspo3 in the treatment of Sdc-associated disorders and for Sdc antagonists in the treatment of Rspo2- and/or Rspo3-associated disorders.
    Type: Application
    Filed: February 10, 2017
    Publication date: June 1, 2017
    Applicant: Deutsches Krebsforschungszentrum
    Inventors: Christof NIEHRS, Andrei GLINKA, Bisei OKAWARA
  • Methods of treating cancer using chemovirotherapy
    Patent number: 9664684
    Abstract: Described is a diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy, comprising exposing primary tumor cells from a patient, e.g., tumor cells obtained from a brain tumor or pancreatic cancer, to (i) a parvovirus and/or (ii) a chemotherapeutic agent or radiotherapy, and determining the reduction of the expression or concentration of ISG15.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: May 30, 2017
    Assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universitaet Heidelberg, Universitaetsklinikum Heidelberg
    Inventors: Nathalia Giese, Jens Werner, Markus Buechler, Thomas Giese, Laurent Daeffler, Celina Czeipluch, Jean Rommelaere, Zahari Raykov
  • Specific TT virus sequences and chimeric TT virus host cell DNA molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity
    Patent number: 9624511
    Abstract: Described are single-stranded new sequences of TT viruses, rearranged TTV sequences and hybrid molecules of a specific TT virus sequence and host cell DNA that are capable of replicating autonomously for use in diagnosis, prevention and treatment of diseases like cancer and autoimmunity. In addition, it relates to the use of such molecules as gene vectors and artificial chromosomes.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: April 18, 2017
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Harald zur Hausen, Ethel-Michele de Villiers
  • ADENOVIRUS DERIVED HELPER VIRUS FOR ENHANCING RECOMBINANT PARVOVIRUS PRODUCTION
    Publication number: 20170073704
    Abstract: Described is an adenovirus derived helper virus which may comprise the adenoviral DNA sequences for E2a, S4 (orf6), the VA1 RNA gene, and the parvovirus VP capsid gene unit. Also described is a method of efficiently preparing a recombinant parvovirus (particle) which is based on the use of various adenoviral derived helper viruses/vectors.
    Type: Application
    Filed: September 26, 2012
    Publication date: March 16, 2017
    Applicant: DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Nazim EL-ANDALOUSSI, Antonio MARCHINI, Jean ROMMELAERE, Barbara LEUCHS, Max ENDELE
  • Cancer therapy with a parvovirus combined with an HDAC inhibitor
    Patent number: 9592260
    Abstract: Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: March 14, 2017
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Antonio Marchini, Jean Rommelaere, Nazim El-Andaloussi, Georgi Hristov, Junwei Li